Literature DB >> 1341931

Cost-effectiveness guidelines for reimbursement of pharmaceuticals: is economic evaluation ready for its enhanced status?

M Drummond.   

Abstract

Mesh：

Year:  1992        PMID： 1341931     DOI： 10.1002/hec.4730010202

Source DB:  PubMed          Journal:  Health Econ        ISSN： 1057-9230            Impact factor:   3.046


× No keyword cloud information.
  18 in total

Review 1.  Real world designs in economic evaluation. Bridging the gap between clinical research and policy-making.

Authors:  R Baltussen; R Leidl; A Ament
Journal:  Pharmacoeconomics       Date:  1999-11       Impact factor: 4.981

2.  Regulation of the pharmaceutical industry and now pharmacoeconomic research?

Authors:  N E Wells
Journal:  Pharmacoeconomics       Date:  1992-12       Impact factor: 4.981

3.  Cost-effectiveness analysis: obstacles to standardisation and its use in regulating pharmaceuticals.

Authors:  B R Luce
Journal:  Pharmacoeconomics       Date:  1993-01       Impact factor: 4.981

4.  Cost-per-QALY league tables: their role in pharmacoeconomic analysis.

Authors:  J M Mason
Journal:  Pharmacoeconomics       Date:  1994-06       Impact factor: 4.981

Review 5.  Economic evaluation of pharmaceuticals: a European perspective.

Authors:  M Drummond; F Rutten; A Brenna; C G Pinto; B Horisberger; B Jönsson; C Le Pen; J Rovira; M G von der Schulenburg; H Sintonen
Journal:  Pharmacoeconomics       Date:  1993-09       Impact factor: 4.981

Review 6.  Cost effectiveness of smoking-cessation therapies. Interpretation of the evidence-and implications for coverage.

Authors:  K E Warner
Journal:  Pharmacoeconomics       Date:  1997-06       Impact factor: 4.981

Review 7.  Methodological issues in economic assessments of new therapies. The case of colony-stimulating factors.

Authors:  M Drummond; J Menzin; G Oster
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

8.  The emerging government requirement for economic evaluation of pharmaceuticals.

Authors:  M Drummond
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

9.  Issues in the conduct of economic evaluations of pharmaceutical products.

Authors:  M F Drummond
Journal:  Pharmacoeconomics       Date:  1994-11       Impact factor: 4.981

10.  Cost effectiveness analysis of neonatal extracorporeal membrane oxygenation based on four year results from the UK Collaborative ECMO Trial.

Authors:  S Petrou; L Edwards
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2004-05       Impact factor: 5.747
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.